Pharmaceutical Companies

Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.

The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.

The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.

Varipulse Pro will receive prominent visibility at the European Heart Rhythm Association (EHRA) annual meeting, where J&J plans to conduct live procedure demonstrations and offer practical training sessions for healthcare professionals.

Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners co-led the financing initiative.

This shift applies to all three Merck vaccines distributed by Zhifei: Gardasil, the rotavirus vaccine RotaTeq, and the pneumococcal vaccine Pneumovax 23.

The medication works as an add-on therapy alongside intranasal corticosteroids for patients whose condition fails to respond adequately to systemic corticosteroids or surgical intervention.

C4 Therapeutics will use its proprietary TORPEDO platform to design the degrader payloads, while Roche will oversee antibody selection, conjugation chemistry, preclinical testing, and clinical development

The Maisons-Alfort plant, which previously operated under Sanofi’s ownership, specializes in fill-finish manufacturing at commercial scale.

The initiative recognizes that pharmacists serve as critical figures in healthcare, often representing the first and most accessible point of contact for millions of Egyptians seeking guidance on everyday health concerns.